Hired and Retired: Controversies at the top
(Image: Getty/AndreyPopov)
The new year has led to a new look to executive boards across the pharma industry, but the movement has arrived with a degree of intrigue in some cases.
A renowned scientist arrives at AstraZeneca, but only shortly after having to relinquish their previous position due to controversial non-disclosure of industry payments. Vertex also terminated the employment of a member of its C-suite on the grounds that their ‘personal behaviour’ was not sufficiently adequate to stay with the company.
